Ma Xuedi, Wang Yang, Chen Yongwu, Lian Yufei, Zhao Xiaoyu, He Xuan, Qiu Yue, Han Sheng, Liu Lihong, Wang Chen
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
State Key Laboratory of Cardiovascular Disease, Department of Medical Research and Biometrics Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Pharmacol. 2024 Jul 29;15:1448986. doi: 10.3389/fphar.2024.1448986. eCollection 2024.
Patients with Chronic Obstructive Pulmonary Disease (COPD) frequently face substantial medication burdens. Follow-up care on medication management is critical in achieving disease control. This study aimed to analyze the complexity of COPD-specific medication and determine how it impacted patients' attendance on follow-up care.
This multicenter study includes patients with COPD from 1,223 hospitals across 29 provinces in China from January 2021 to November 2022. The medication Regimen Complexity Index (MRCI) score was used to measure COPD-specific medication complexity. The association between medication complexity and follow-up care attendance was evaluated using the Cox Proportional Hazard Model.
Among 16,684 patients, only 2,306 (13.8%) returned for follow-up medication management. 20.3% of the patients had high complex medication regimen (MRCI score >15.0). The analysis revealed that compared to those with less complex regimens, patients with more complex medication regimens were significantly less likely to attend the follow-up medication care, with a Hazard Ratio (HR) of 0.82 (95% Confidence Interval [CI], 0.74-0.91). Specifically, patients with more complex dosage forms were 51% less likely to attend the follow-up care (95% CI, 0.43-0.57). This pattern was especially marked among male patients, patients younger than 65 years, and those without comorbid conditions.
Higher medication complexity was associated with a decreased likelihood of attending follow-up care. To promote care continuity in chronic disease management, individuals with complex medication regimens should be prioritized for enhanced education. Furthermore, pharmacists collaborating with respiratory physicians to deprescribe and simplify dosage forms should be considered in the disease management process.
慢性阻塞性肺疾病(COPD)患者经常面临沉重的药物负担。药物管理的后续护理对于实现疾病控制至关重要。本研究旨在分析COPD特异性药物治疗的复杂性,并确定其如何影响患者的后续护理就诊率。
这项多中心研究纳入了2021年1月至2022年11月期间来自中国29个省份1223家医院的COPD患者。使用药物治疗方案复杂性指数(MRCI)评分来衡量COPD特异性药物治疗的复杂性。使用Cox比例风险模型评估药物治疗复杂性与后续护理就诊率之间的关联。
在16684名患者中,只有2306名(13.8%)返回进行后续药物管理。20.3%的患者有高复杂性药物治疗方案(MRCI评分>15.0)。分析显示,与治疗方案较简单的患者相比,药物治疗方案较复杂的患者参加后续药物护理的可能性显著降低,风险比(HR)为0.82(95%置信区间[CI],0.74-0.91)。具体而言,药物剂型较复杂的患者参加后续护理的可能性降低51%(95%CI,0.43-0.57)。这种模式在男性患者、65岁以下患者和无合并症患者中尤为明显。
较高的药物治疗复杂性与较低的后续护理就诊可能性相关。为了促进慢性病管理中的护理连续性,应优先对药物治疗方案复杂的个体加强教育。此外,在疾病管理过程中应考虑药剂师与呼吸内科医生合作减少用药并简化药物剂型。